Adaptive Biotechnologies Corporation (MUN:1HM)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.79B +77.0% |
| Revenue (ttm) | 256.21M +55.9% |
| Net Income | -43.09M |
| EPS | -0.28 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 184 |
| Open | 11.41 |
| Previous Close | 11.68 |
| Day's Range | 11.41 - 11.41 |
| 52-Week Range | 6.89 - 15.32 |
| Beta | n/a |
| RSI | 58.74 |
| Earnings Date | May 5, 2026 |
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minima... [Read more]
Financial Performance
In 2025, Adaptive Biotechnologies's revenue was $276.98 million, an increase of 54.77% compared to the previous year's $178.96 million. Losses were -$59.50 million, -62.69% less than in 2024.
Financial numbers in USD Financial StatementsNews
Adaptive Biotechnologies price target lowered to $18 from $21 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Adaptive Biotechnologies (ADPT) to $18 from $21 and keeps an Equal Weight rating on the shares. Published first on…
Adaptive Biotechnologies price target lowered to $19 from $21 at JPMorgan
JPMorgan lowered the firm’s price target on Adaptive Biotechnologies (ADPT) to $19 from $21 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Adaptive Biotechnologies price target raised to $21 from $19 at TD Cowen
TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $19 and keeps a Buy rating on the shares. The firm said the company delivered another…
Adaptive Biotechnologies Earnings Call Transcript: Q1 2026
Q1 revenue grew 45% year-over-year, led by 53% MRD growth and record clinical volumes. Sequencing gross margin rose to 70%, and full-year MRD guidance was raised to $260M–$270M. Strong adoption, operational efficiency, and expanding pharma partnerships support continued momentum.
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics...
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys...
Adaptive Biotechnologies Transcript: TD Cowen 46th Annual Health Care Conference
Strong volume growth, guideline inclusions, and pricing improvements are driving double-digit expansion, with EMR integration and clinical data supporting further adoption. International expansion is capital-efficient, and the technology remains the gold standard in MRD, with robust financial margins and a promising immune medicine pipeline.
Adaptive Biotechnologies price target raised to $21 from $20 at TD Cowen
TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $20 and keeps a Buy rating on the shares. The firm updated its model following Q4…
Adaptive Biotechnologies price target raised to $22 from $21 at BTIG
BTIG raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $21 and keeps a Buy rating on the shares after its Q4 results. The company is firing…
Adaptive Biotechnologies price target raised to $21 from $20 at JPMorgan
JPMorgan analyst Sebastian Sandler raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $20 and keeps an Overweight rating on the shares. The firm views the company’s…
Adaptive Biotechnologies Earnings Call Transcript: Q4 2025
Achieved 55% revenue growth and 68% lower cash burn in 2025, with MRD profitability and strong clonoSEQ test volume growth. 2026 guidance targets 22% MRD revenue growth, over 30% test volume increase, and positive company-wide adjusted EBITDA and free cash flow by year-end.
Adaptive Biotechnologies reports Q4 EPS (9c), consensus (18c)
Reports Q4 revenue $71.68M, consensus $60.9M. The MRD business, which contributed 86% of revenue in the fourth quarter and 77% of revenue in the full year, grew 54% and 46%…
Adaptive Biotechnologies sees FY26 operating expenses $350M-$360M
The company said, “Adaptive Biotechnologies (ADPT) expects full year revenue for the MRD business to be between $255 million and $265 million. No revenue guidance is provided for the Immune…
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetic...
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies price target raised to $21 from $20 at Guggenheim
Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $20 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for…
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies Transcript: 44th Annual J.P. Morgan Healthcare Conference
MRD testing volumes and revenues continue to grow, driven by blood-based testing, community expansion, and updated clinical guidelines. ASPs are rising, with a clear path to $1,700–$1,800 by 2029, and the company expects positive adjusted EBITDA and free cash flow in 2026. Immune medicine is advancing through data partnerships and predictive modeling.
Adaptive Biotechnologies sees Q4 revenue $72M, consensus $59.38M
Total revenue for the fourth quarter and full year 2025 was approximately $72M and $277M, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024. Cash,…
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies price target raised to $20 from $19 at TD Cowen
TD Cowen raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $20 from $19 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnostics…
Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech
Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive Biotechnologies, has raised fresh cash as part of an initial closing of a Series A inve...
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst...
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases.
Adaptive Biotechnologies enters two licensing agreements with Pfizer
Adaptive Biotechnologies (ADPT) announced two non-exclusive agreements with Pfizer (PFE) to leverage Adaptive’s proprietary T-cell receptor discovery capabilities and large-scale immune receptor antig...